Performance Enhancing Drugs Global Market Report 2025

The performance enhancing drugs market size has grown strongly in recent years. It will grow from $10.79 billion in 2024 to $11.42 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. Growth during the historic period was driven by increased enthusiasm for competitive sports, a heightened focus on body image and physical appearance, broader online accessibility to PEDs, historical use in military and defense contexts, and a rise in off-label usage across general populations.

The performance enhancing drugs market size is expected to see strong growth in the next few years. It will grow to $14.16 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. Key drivers in the forecast period include rising investment in products that enhance vitality and combat aging, a surge in conditions linked to fatigue and chronic stress, expanding adoption in emerging markets, increased utilization of gene doping and synthetic biology, and growing interest in cognitive enhancement within educational and professional environments. Prominent trends anticipated include innovations in pharmaceutical drug formulations, the use of AI in drug discovery, tech-driven personalized supplements, breakthroughs in gene editing and synthetic biology, and continued progress in nootropic compound development.

The rising interest in fitness activities is expected to propel the growth of the performance enhancing drugs market going forward. Fitness activities refer to physical exercises or movements performed to improve or maintain one’s health, strength, flexibility, or overall physical condition. The increasing interest in fitness activities is primarily driven by greater health awareness, as more individuals recognize the importance of physical exercise in preventing chronic diseases and maintaining overall well-being. Performance enhancing drugs improve physical capabilities such as strength, endurance, and recovery, thereby supporting individuals in achieving greater results in fitness activities by accelerating muscle growth, reducing fatigue, and enabling longer and more intense training sessions. For instance, in November 2024, according to the report published by PureGym, a UK-based health company, in 2024, 48% of individuals are taking part in regular exercise, which is a 3% increase from the previous year. Therefore, the growing interest in fitness activities is driving the growth of the performance enhancing drugs market.

The surge in sports participation is expected to propel the growth of the performance enhancing drugs market going forward. Sports participation refers to the act of taking part in organized or informal physical activities or games, either individually or as part of a team. This increase in sports participation is primarily due to rising awareness of the health benefits of physical activity, as more people recognize that regular exercise can improve cardiovascular health, boost mental well-being, and reduce the risk of chronic diseases. Performance enhancing drugs aid in sports participation by improving physical attributes such as strength, endurance, speed, and recovery time, allowing athletes to train more intensively, reduce fatigue, overcome physical limitations, and maintain peak performance during competitive events. For instance, in October 2024, according to the Sports & Fitness Industry Association, a US-based non-profit organization, SFIA data indicated that participation in team sports increased by about 8 million people in 2023 compared to the previous year, marking an 11% growth from 2022. Therefore, the increase in sports participation is fueling the growth of the performance enhancing drugs market.

Major companies operating in the performance enhancing drugs market are focusing on developing solutions such as nootropic supplements aimed at enhancing cognitive functions such as memory, focus, and mental clarity. Nootropic supplements refer to substances - natural, synthetic, or a combination - designed to enhance cognitive functions including memory, learning, attention, focus, and mental clarity. For instance, in February 2022, Jones Soda, a US-based beverage company, launched a nootropic supplement beverage formulated to support focus, mental clarity, and brain health. The product is inspired by Mike Tyson’s personal journey of healing brain injury and emotional trauma through natural, fungal, and plant-based remedies. The beverage contains a proprietary blend of nootropics and adaptogens, including L-theanine, N-acetyl tyrosine, lion’s mane mushroom extract, and essential B vitamins (B3, B5, B6, and B12), along with a small amount of caffeine. This formulation is intended to deliver a clean energy boost and cognitive support without the typical mushroom-based taste. The drink is available in two flavors, Tyson’s Punch and Tiger’s Blood, both offering fruity, crisp, and flavorful profiles in line with Jones Soda’s reputation for craft beverages.

Major players in the performance enhancing drugs market are Pfizer Inc., Bayer AG, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Organon & Co, Douglas Laboratories, Balkan Pharmaceuticals, Onnit Labs LLC, Geneza Pharmaceuticals, Taj Pharmaceuticals, British Dragon, Aspen API, Zhengzhou Pharmaceutical Co., Hilma Biocare, and Sciroxx.

North America was the largest region in the performance enhancing drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in performance enhancing drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the performance enhancing drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Performance-enhancing drugs are substances designed to boost physical or mental performance by enhancing strength, endurance, focus, or recovery. These substances are frequently used with the intent of improving athletic output, accelerating progress, and achieving better results from training. Their usage is often linked to a strong ambition for excellence and success in competitive environments.

The primary types of performance-enhancing drugs include stimulants, anabolic steroids, peptide hormones, beta-2 agonists, and others. Stimulants work by activating the central nervous system, resulting in heightened alertness, increased energy levels, and improved physical capabilities. These substances are used in a range of scenarios, such as by athletes, students, military personnel, among others, and are distributed via various channels like online platforms, pharmacies, specialty outlets, gyms, and direct sales. The target end users include professional and amateur athletes, bodybuilders, fitness enthusiasts, and patients with chronic health conditions.

The performance enhancing drugs market research report is one of a series of new reports that provides performance enhancing drugs market statistics, including performance enhancing drugs industry global market size, regional shares, competitors with the performance enhancing drugs market share, performance enhancing drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the performance enhancing drugs industry. This performance enhancing drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The performance enhancing drugs market consists of sales of clear float performance-enhancing drugs, steroid precursors (prohormones), human growth hormone (hGH), erythropoietin (EPO), and creatine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.